Biodesix financials
$29.14−4.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.9M | $25.6M | $28.8M | $21.8M | $20.0M | $18.0M | $20.4M | $18.2M | $17.9M | $14.8M | $14.7M | $13.5M |
| Gross profit | $22.0M | $21.4M | $23.9M | $17.7M | $16.0M | $14.3M | $16.1M | $14.0M | $14.0M | $11.6M | $1.7M | $13.5M |
| Gross margin | 82.1% | 83.5% | 83.0% | 81.1% | 79.9% | 79.4% | 78.7% | 77.0% | 78.4% | 78.6% | 11.3% | 100.0% |
| Operating income | -$5.4M | -$6.2M | -$2.0M | -$7.1M | -$9.7M | -$9.1M | -$6.6M | -$8.6M | -$8.2M | -$11.0M | -$6.9M | -$7.2M |
| Net income | -$7.3M | -$7.8M | -$4.0M | -$8.7M | -$11.5M | -$11.1M | -$8.3M | -$10.3M | -$10.8M | -$13.6M | -$9.1M | -$10.9M |
| Net margin | −27.1% | −30.5% | −13.8% | −40.0% | −57.3% | −61.8% | −40.4% | −56.5% | −60.3% | −91.9% | −62.3% | −81.2% |
| Diluted EPS | $-0.71 | $-0.81 | $-0.49 | $-1.16 | $-1.56 | $-1.52 | $-0.57 | $-1.40 | $-1.60 | $-2.80 | $-1.98 | $-2.80 |
| EBITDA | -$4.0M | -$4.8M | -$579.0K | -$5.6M | -$8.3M | -$7.6M | -$5.1M | -$7.1M | -$6.8M | -$9.5M | -$5.9M | -$6.4M |
| Operating cash flow | -$1.6M | -$10.2M | $778.0K | -$8.9M | -$6.6M | -$8.6M | -$4.1M | -$10.7M | -$18.6M | -$15.3M | -$12.3M | -$3.8M |
| Free cash flow | -$1.8M | -$10.2M | $692.0K | -$8.9M | -$6.6M | -$8.7M | -$4.9M | -$10.9M | -$20.5M | -$15.5M | -$15.3M | -$9.7M |
| Diluted shares | 10.3M | 9.7M | 8.1M | 7.5M | 7.3M | 7.3M | 14.4M | 7.3M | 6.4M | 4.9M | 4.6M | 4.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.0M | $25.6M | $19.0M | $16.6M | $20.7M | $17.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $46.8M | $46.5M | $47.5M | $47.1M | $46.8M | $36.7M |
| Total assets | $95.3M | $94.6M | $87.5M | $88.7M | $87.7M | $86.2M |
| Total liabilities | $86.2M | $85.5M | $89.9M | $90.4M | $86.6M | $75.2M |
| Shareholders' equity | $9.1M | $9.1M | -$2.5M | -$1.7M | $1.1M | $11.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology